The TriStem technology offers the potential to prepare large
quantities of stem cells from the patient's own blood
by the process of retrodifferentiation and, therefore,
provides
substantial benefits, both in terms of cost effectiveness
and potential clinical outcomes to be gained from infusing
higher concentrations of stem cells including more committed
subsets. In addition, the technology provides a new source
of stem cell supply which
represents a quantum leap in yield when compared with current
harvesting methods. Significantly, the procedure reduces
the need for a donor, nor does it require
potentially uncomfortable invasive surgical procedures.
Retrodifferentiation is a process during which mature, specialised cells can revert back
to a more primitive, immature cell stage. These retrodifferentiated stem cells are then
capable of redifferentiating into a variety of cell types. Therefore, the process itself
has the potential to reconstitute an entire human tissue such as blood, neurones, muscle
etc. |
